Cancer drug development and drug testing processes are being successfully accelerated with the use of primary tumor-derived models because they reliably represent tumor heterogeneity, morphology, and complex genetic and molecular composition. However, the complexity of performing 3D assays remains a hurdle for adoption when it comes to methods for compound screening.

Learn how Tulane University worked with Molecular Devices in their search to find more relevant therapies for clinically aggressive cancers by developing a method to simplify, automate, and scale up complex 3D cell-based assays. They’ll also share advanced analysis approaches that deliver more information about these cellular systems, disease phenotypes, and compound effects.

Additional takeaways include: 

  • Advantages of patient-derived organoids over other models
  • The influence these models have on the drug discovery pipeline
  • How automation and phenotypic profiling can be used to identify new and better drugs for cancer treatment

Register to download on-demand webinar now